Trinomab Biotech, a Chinese clinical-stage biopharmaceutical firm with operations globally, announced on Tuesday the completion of its pre-IPO financing at about 750 million yuan ($104.4 million) to advance its product pipeline.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
